The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee

  • Kim, Moon Jin (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Young Sam (Department of Internal Medicine, Dong-A University Hospital) ;
  • Oh, Sung Yong (Department of Internal Medicine, Dong-A University Hospital) ;
  • Lee, Suee (Department of Internal Medicine, Dong-A University Hospital) ;
  • Choi, Young-Jin (Department of Internal Medicine, Pusan National University Hospital) ;
  • Seol, Young Mi (Department of Internal Medicine, Pusan National University Hospital) ;
  • Park, Min Jae (Department of Internal Medicine, Pusan National University Yangsan Hospital) ;
  • Kim, Ki Hyang (Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Park, Lee Chun (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Kang, Jung Hun (Department of Internal Medicine, Gyeongsang National University Hospital) ;
  • Hwang, In-Gyu (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Lee, Soon Il (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Lim, Seung Taek (Department of Internal Medicine, Konyang University Hospital) ;
  • Kim, Hyo Song (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Lim, Ho Yeong (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Rha, Sun Young (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kim, Hyo-Jin (Department of Internal Medicine, Dong-A University Hospital)
  • Received : 2015.06.07
  • Accepted : 2015.12.31
  • Published : 2018.03.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma. Methods: Eligible patients for this retrospective analysis were initially diagnosed with bladder adenocarcinoma and presented with a clinically no other primary site of origin. The collected data included age, gender, performance status, stage, hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, response to treatment, presence of relapse, last status of patient, and last date of follow-up. Results: We retrospectively reviewed 29 patients, who were treated with chemotherapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7% of the patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were treated with 5-f luorouracil based chemotherapy, five were gemcitabine based, three were taxane and others. Thirteen of them achieved complete response (10.3%) or partial response (34.5%). Median progression-free survival (PFS) and overall survival (OS) for all patients were 10.6 months (95% confidence interval [CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), respectively. The cases of urachal adenocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, respectively). Conclusions: Even though bladder adenocarcinoma had been observed moderate effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive form of bladder cancer. PFS and OS were short especially in urachal carcinoma.

Keywords

Acknowledgement

Supported by : Dong-A University

References

  1. Zhong M, Gersbach E, Rohan SM, Yang XJ. Primary adenocarcinoma of the urinary bladder: differential diagnosis and clinical relevance. Arch Pathol Lab Med 2013;137:371-381. https://doi.org/10.5858/arpa.2012-0076-RA
  2. Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases. Histopathology 2000;36:32-40. https://doi.org/10.1046/j.1365-2559.2000.00797.x
  3. Bardales RH, Pitman MB, Stanley MW, Korourian S, Suhrland MJ. Urine cytology of primary and secondary urinary bladder adenocarcinoma. Cancer 1998;84:335-343. https://doi.org/10.1002/(SICI)1097-0142(19981225)84:6<335::AID-CNCR4>3.0.CO;2-W
  4. Hong JY, Choi MK, Uhm JE, et al. Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. Med Oncol 2009;26:186-192. https://doi.org/10.1007/s12032-008-9106-7
  5. Zhang J, Wu J. Options for diagnosis and treatment of urachal carcinoma. Asia Pac J Clin Oncol 2013;9:117-122. https://doi.org/10.1111/j.1743-7563.2012.01592.x
  6. Akamatsu S, Takahashi A, Ito M, Ogura K. Primary signet- ring cell carcinoma of the urinary bladder. Urology 2010;75:615-618. https://doi.org/10.1016/j.urology.2009.06.065
  7. Romics I, Szekely E, Szendroi A. Signet-ring cell carcinoma arising from the urinary bladder. Can J Urol 2008;15:4266-4268.
  8. Smith AK, Hansel DE, Jones JS. Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. Urology 2008;71:915-918. https://doi.org/10.1016/j.urology.2007.11.079
  9. Zhang H, Jiang H, Wu Z, Fang Z, Fan J, Ding Q. Primary adenocarcinoma of the urinary bladder: a single site analysis of 21 cases. Int Urol Nephrol 2013;45:107-111. https://doi.org/10.1007/s11255-012-0305-y
  10. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol 2003;44:672-681. https://doi.org/10.1016/S0302-2838(03)00416-0
  11. Manunta A, Vincendeau S, Kiriakou G, Lobel B, Guille F. Non-transitional cell bladder carcinomas. BJU Int 2005;95:497-502. https://doi.org/10.1111/j.1464-410X.2005.05327.x
  12. Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 2007;69:255-259. https://doi.org/10.1016/j.urology.2006.10.029
  13. Siefker-Radtke A. Urachal adenocarcinoma: a clinician’s guide for treatment. Semin Oncol 2012;39:619-624. https://doi.org/10.1053/j.seminoncol.2012.08.011
  14. Miyata Y, Sagara Y, Matsuo T, et al. Response of recurrent urachal cancer to gemcitabine and cisplatin therapy: a case report and literature review. Anticancer Res 2011;31:2335-2338.
  15. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-1055. https://doi.org/10.1200/JCO.1990.8.6.1050
  16. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012;30:1107-1113. https://doi.org/10.1200/JCO.2011.38.6979
  17. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191-199.
  18. Ismaili N, Amzerin M, Flechon A. Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol 2011;4:35. https://doi.org/10.1186/1756-8722-4-35
  19. Carballido EM, Rosenberg JE. Optimal treatment for metastatic bladder cancer. Curr Oncol Rep 2014;16:404. https://doi.org/10.1007/s11912-014-0404-2
  20. Wright JL, Porter MP, Li CI, Lange PH, Lin DW. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 2006;107:721-728. https://doi.org/10.1002/cncr.22059
  21. Mostofi FK, Thomson RV, Dean AL Jr. Mucous adenocarcinoma of the urinary bladder. Cancer 1955;8:741-758. https://doi.org/10.1002/1097-0142(1955)8:4<741::AID-CNCR2820080417>3.0.CO;2-C
  22. Dandekar NP, Dalal AV, Tongaonkar HB, Kamat MR. Adenocarcinoma of bladder. Eur J Surg Oncol 1997;23:157-160. https://doi.org/10.1016/S0748-7983(97)80012-1

Cited by

  1. Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma vol.3, pp.6, 2020, https://doi.org/10.1002/iju5.12210
  2. Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study vol.11, pp.None, 2018, https://doi.org/10.3389/fonc.2021.671969